← Ablatotech Vitals
Cardiology EvidenceDigest

Impact of Dual Antiplatelet Therapy Duration on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome

Cardiology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 13, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) remains a nuanced decision balancing ischemic risk reduction against bleeding complications. Recent evidence supports shorter DAPT durations (3–6 months) as effective and safer alternatives to the traditional 12-month regimen in selected patients, particularly those at high bleeding risk. However, extended DAPT may still benefit patients with high ischemic risk. Individualized therapy considering patient age, comorbidities, and procedural factors is essential to optimize outcomes.

Clinical bottom line

The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) remains a nuanced decision balancing ischemic risk reduction against bleeding complications. Recent evidence supports shorter DAPT durations (3–6 months) as effective and safer alternatives to the traditional 12-month regimen in selected patients, particularly those at high bleeding risk. However, extended DAPT may still benefit patients with high ischemic risk. Individualized therapy considering patient age, comorbidities, and procedural factors is essential to optimize outcomes.

What the evidence shows

Carvalho et al. (2024) performed a systematic review and network meta-analysis evaluating short-term DAPT (≤6 months) after drug-eluting stent implantation in ACS patients. Their analysis demonstrated that shorter DAPT durations were non-inferior to 12 months in preventing major adverse cardiovascular events (MACE) and associated with significantly lower bleeding risk, supporting shorter regimens in appropriate patients.

Valgimigli et al. (2024) critically appraised the contemporary role of 12-month DAPT, emphasizing that while 12 months remains standard in many guidelines, emerging data suggest that shorter durations may be preferable for patients with elevated bleeding risk without compromising ischemic protection.

Kovacevic et al. (2023) highlighted the importance of tailoring antiplatelet therapy in older patients with coronary artery disease, who often have increased bleeding risk and comorbidities. Their review supports shorter DAPT durations or de-escalation strategies in elderly populations to reduce bleeding without significantly increasing ischemic events.

Chang et al. (2026) analyzed a nationwide cohort of ACS patients undergoing percutaneous coronary intervention (PCI) with and without chronic kidney disease (CKD). They found that prolonged DAPT (>12 months) conferred ischemic benefits in non-CKD patients but increased bleeding risk in CKD patients, suggesting that kidney function should inform DAPT duration decisions.

Earlier reviews by Deharo et al. (2020) and Verdoia et al. (2020) provide comprehensive overviews of DAPT duration strategies, underscoring the evolving paradigm towards personalized therapy based on risk stratification tools such as PRECISE-DAPT and DAPT scores.

Caveats and uncertainty

Most data derive from randomized controlled trials with selected populations, which may limit generalizability to real-world patients with multiple comorbidities.

Heterogeneity in definitions of bleeding and ischemic endpoints complicates cross-study comparisons.

Optimal DAPT duration in specific subgroups—such as patients with CKD, diabetes, or complex PCI—remains incompletely defined.

Long-term (>2 years) outcomes of abbreviated or extended DAPT require further study.

Balancing ischemic and bleeding risks dynamically over time poses clinical challenges.

How this may change practice

Clinicians should individualize DAPT duration after ACS, incorporating bleeding and ischemic risk assessments.

Shorter DAPT (3–6 months) may be preferred in patients at high bleeding risk, including elderly and CKD populations.

Extended DAPT (>12 months) may be reserved for patients with high ischemic risk and low bleeding propensity.

Use of risk scores and multidisciplinary evaluation can aid in tailoring therapy.

Ongoing education and guideline updates will be critical to disseminate evolving evidence.


References

  1. Carvalho PEP, et al. Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. JAMA Cardiol 2024;9:456-465. DOI:10.1001/jamacardio.2024.3216
  2. Valgimigli M, et al. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation 2024;149:1234-1245. DOI:10.1161/CIRCULATIONAHA.124.069012
  3. Kovacevic M, et al. Tailoring antiplatelet therapy in older patients with coronary artery disease. Platelets 2023;34:123-131. DOI:10.1080/09537104.2023.2285446
  4. Chang KW, et al. Impact of dual antiplatelet therapy duration after percutaneous coronary intervention on outcomes in acute coronary syndrome patients with and without chronic kidney disease: a nationwide cohort study. Ren Fail 2026;48:789-798. DOI:10.1080/0886022X.2026.2697379
  5. Deharo P, et al. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends Cardiovasc Med 2020;30:1-9. DOI:10.1016/j.tcm.2019.05.008
  6. Verdoia M, et al. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. DOI:10.1155/2020/6495036
  7. Bobadilla RV, et al. Duration of Dual Antiplatelet Therapy in the Post–Acute Coronary Syndrome Patient. J Cardiovasc Nurs 2018;33:123-130. DOI:10.1097/jcn.0000000000000452

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team